The International SSRI Pharmacogenomics Consortium (ISPC): A genome-wide association study of antidepressant treatment response

Translational Psychiatry

Volumn 5, Issue 4, 2015, Pages

  Biernacka, J M ^a   Sangkuhl, K ^b   Jenkins, G ^a   Whaley, R M ^b   Barman, P ^a   Batzler, A ^a   Altman, R B ^b,c   Arolt, V ^d   Brockmoller J ^e   Chen, C H ^f   Domschke, K ^g   Hall Flavin, D K ^a   Hong, C J ^h,i   Illi, A ^j   Ji, Y ^k   Kampman, O ^j,l   Kinoshita, T ^m   Leinonen, E ^j,n   Liou, Y J ^h,i   Mushiroda, T ^o   Nonen, S ^p   Skime, M K ^a   Wang, L ^k   Baune, B T ^q   Kato, M ^m   Liu, Y L ^r   Praphanphoj, V ^s   Stingl, J C ^t   Tsai, S J ^h,i   Kubo, M ^o   Klein, T E ^b   Weinshilboum, R ^k   more..

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Stanford University   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^k MAYO GRADUATE SCHOOL   (United States)

^l SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^m KANSAI MEDICAL UNIVERSITY   (Japan)

ⁿ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^o RIKEN Center for Integrative Medical Sciences   (Japan)

^p HYOGO COLLEGE OF MEDICINE   (Japan)

^q UNIVERSITY OF ADELAIDE   (Australia)

^r NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^s MINISTRY OF PUBLIC HEALTH   (Thailand)

^t Federal Institute for Drugs and Medical Devices   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; DNA; GLYCOSYLPHOSPHATIDYLINOSITOL; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE PSEUDOGENE 4 PROTEIN; INTEGRIN; INTEGRIN ALPHA 11; MICROCEPHALIN 1; MYOTUBULARIN RELATED PROTEIN 12; NEU DIFFERENTIATION FACTOR; PHOSPHORIBOSYLTRANSFERASE; PROTEIN; PROTEIN SERINE THREONINE KINASE; RYANODINE RECEPTOR 3; SERINE THREONINE KINASE 39; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; V SET AND TRANSMEMBRANE DOMAIN CONTAINING 5 PROTEIN; VON WILLEBRAND FACTOR; ANTIDEPRESSANT AGENT; BRD2 PROTEIN, HUMAN; MCPH1 PROTEIN, HUMAN; NERVE PROTEIN; NRG1 PROTEIN, HUMAN; SCN7A PROTEIN, HUMAN; STK39 PROTEIN, HUMAN; VOLTAGE GATED SODIUM CHANNEL;

5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MAPPING; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; GENETICS; MIDDLE AGED; PHARMACOGENETICS; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUREGULIN-1; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84990909819     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.47     Document Type: Article

References (48)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 109(Suppl 420): 21-27.
2. Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: A retrospective US claims study. Clin Ther 2012; 34: 113-123.
3. Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE. A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiol Drug Saf 2008; 17: 697-706.
4. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 487-520.
5. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138.
6. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966-975.
7. Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: Genome-wide associations and functional genomics. Pharmacogenomics J 2013; 13: 456-463.
8. Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: A brief review. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1553-1557.
9. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564.
10. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A tool for genome-wide complex trait analysis. Am J Hum Genet 2011; 88: 76-82.
11. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679-682.
12. Uher R, GENDEP Investigators, MARS Investigators, STAR∗D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170: 207-217.
13. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: A genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9: E1001326.
14. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR∗D) study. Psychiatr Clin North Am 2003; 26: 457-494, x.
15. Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD et al. Treatment outcomes of depression: The pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 2014; 34: 313-317.
16. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: The impact of early symptomatic improvement. Can J Psychiatry 2012; 57: 782-788.
17. Stassen H, Anghelescu IG, Angst J, Boker H, Lotscher K, Rujescu D et al. Predicting response to psychopharmacological treatment: Survey of recent results. Pharmacopsychiatry 2011; 44: 263-272.
18. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344-353.
19. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
20. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009; 84: 210-223.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
22. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15: 1995-2002.
23. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-892.
24. Georgieva L, Dimitrova A, Ivanov D, Nikolov I, Williams NM, Grozeva D et al. Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry 2008; 64: 419-427.
25. Bousman CA, Yung AR, Pantelis C, Ellis JA, Chavez RA, Nelson B et al. Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Transl Psychiatry 2013; 3: E251.
26. Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010; 44: 1205-1213.
27. Mahar I, Tan S, Davoli MA, Dominguez-Lopez S, Qiang C, Rachalski A et al. Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-like effects. PLoS One 2011; 6: E26610.
28. Wang N, Zhang GF, Liu XY, Sun HL, Wang XM, Qiu LL et al. Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine. J Mol Neurosci 2014; 54: 211-218.
29. Jackson AP, McHale DP, Campbell DA, Jafri H, Rashid Y, Mannan J et al. Primary autosomal recessive microcephaly (MCPH1) maps to chromosome 8p22-pter. Am J Hum Genet 1998; 63: 541-546.
30. Gruber R, Zhou Z, Sukchev M, Joerss T, Frappart PO, Wang ZQ. MCPH1 regulates the neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the Chk1-Cdc25 pathway. Nat Cell Biol 2011; 13: 1325-1334.
31. Boldrini M, Arango V. Antidepressants, age, and neuroprogenitors. Neuropsychopharmacology 2010; 35: 351-352.
32. Tang SW, Helmeste D, Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J Biol Psychiatry 2012; 13: 402-412.
33. Ishitobi Y, Inoue A, Aizawa S, Masuda K, Ando T, Kawano A et al. Association of microcephalin 1, syntrophin-beta 1, and other genes with automatic thoughts in the Japanese population. Am J Med Genet B Neuropsychiatr Genet 2014; 165: 492-501.
34. Oldmeadow C, Mossman D, Evans TJ, Holliday EG, Tooney PA, Cairns MJ et al. Combined analysis of exon splicing and genome wide polymorphism data predict schizophrenia risk loci. J Psychiatr Res 2014; 52: 44-49.
35. Ozgen HM, van Daalen E, Bolton PF, Maloney VK, Huang S, Cresswell L et al. Copy number changes of the microcephalin 1 gene (MCPH1) in patients with autism spectrum disorders. Clin Genet 2009; 76: 348-356.
36. Murayama T, Ogawa Y. Properties of Ryr3 ryanodine receptor isoform in mammalian brain. J Biol Chem 1996; 271: 5079-5084.
37. Adasme T, Haeger P, Paula-Lima AC, Espinoza I, Casas-Alarcon MM, Carrasco MA et al. Involvement of ryanodine receptors in neurotrophin-induced hippocampal synaptic plasticity and spatial memory formation. Proc Natl Acad Sci USA 2011; 108: 3029-3034.
38. Futatsugi A, Kato K, Ogura H, Li ST, Nagata E, Kuwajima G et al. Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3. Neuron 1999; 24: 701-713.
39. Balatoni CE, Dawson DW, Suh J, Sherman MH, Sanders G, Hong JS et al. Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress. Am J Pathol 2009; 175: 1653-1661.
40. Ramoz N, Cai G, Reichert JG, Silverman JM, Buxbaum JD. An analysis of candidate autism loci on chromosome 2q24-q33: Evidence for association to the STK39 gene. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1152-1158.
41. Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S et al. Genomewide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 2012; 37: 797-807.
42. Bacchelli E, Ceroni F, Pinto D, Lomartire S, Giannandrea M, D'Adamo P et al. A CTNNA3 compound heterozygous deletion implicates a role for alphaT-catenin in susceptibility to autism spectrum disorder. J Neurodev Disord 2014; 6: 17.
43. Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, Girirajan S et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013; 70: 582-590.
44. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J et al. Genomewide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res 2012; 198: 424-429.
45. van den Oord EJ, Kuo PH, Hartmann AM, Webb BT, Moller HJ, Hettema JM et al. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 2008; 65: 1062-1071.
46. Heck A, Pfister H, Czamara D, Muller-Myhsok B, Putz B, Lucae S et al. Evidence for associations between MDGA2 polymorphisms and harm avoidance: Replication and extension of a genome-wide association finding. Psychiatr Genet 2011; 21: 257-260.
47. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984-994.
48. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: Insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011; 68: 1227-1237.